Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.4%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price was down 4.4% on Wednesday . The company traded as low as $8.94 and last traded at $8.97. Approximately 1,368,546 shares changed hands during trading, a decline of 77% from the average daily volume of 5,912,037 shares. The stock had previously closed at $9.38.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday. KeyCorp boosted their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th.

Recursion Pharmaceuticals Trading Down 13.5 %

The firm has a 50-day simple moving average of $8.84 and a two-hundred day simple moving average of $9.92.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The firm had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. During the same quarter last year, the business earned ($0.34) earnings per share. Recursion Pharmaceuticals’s revenue was up 14.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $8.82, for a total transaction of $100,962.54. Following the transaction, the director now directly owns 7,241,308 shares of the company’s stock, valued at $63,868,336.56. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $7.58, for a total transaction of $175,279.92. Following the sale, the chief financial officer now owns 1,231,055 shares of the company’s stock, valued at approximately $9,331,396.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was sold at an average price of $8.82, for a total value of $100,962.54. Following the completion of the transaction, the director now owns 7,241,308 shares in the company, valued at approximately $63,868,336.56. The disclosure for this sale can be found here. Insiders sold 252,806 shares of company stock worth $2,115,737 over the last three months. 15.75% of the stock is owned by insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at approximately $26,000. National Bank of Canada FI lifted its holdings in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $47,000. Oxford Wealth Group LLC bought a new position in shares of Recursion Pharmaceuticals during the first quarter valued at approximately $106,000. Finally, Daiwa Securities Group Inc. raised its position in shares of Recursion Pharmaceuticals by 1,508.6% during the 4th quarter. Daiwa Securities Group Inc. now owns 11,759 shares of the company’s stock worth $116,000 after purchasing an additional 11,028 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.